Goldman Sachs Group (GS)

1,062.75
+27.11 (2.62%)
NYSE· Last Trade: Jun 12th, 6:54 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1,035.64
Open1,053.00
Bid1,062.00
Ask1,064.40
Day's Range1,048.06 - 1,073.74
52 Week Range609.59 - 1,098.36
Volume2,205,732
Market Cap365.00B
PE Ratio (TTM)20.73
EPS (TTM)51.3
Dividend & Yield18.00 (1.69%)
1 Month Average Volume2,295,123

Chart

About Goldman Sachs Group (GS)

Goldman Sachs Group is a leading global investment banking, securities, and investment management firm that provides a wide range of financial services to a diverse client base, including corporations, financial institutions, governments, and individuals. The company engages in various activities, including financial advisory services, underwriting of capital market transactions, asset management, and market making in securities and commodities. It is known for its expertise in mergers and acquisitions, risk management, and investment strategy, leveraging its extensive research capabilities and global reach to deliver innovative solutions in an ever-evolving financial landscape. Read More

News & Press Releases

Why Goldman Sachs (GS) Stock Is Trading Up Today
What Happened? Shares of global investment bank Goldman Sachs (NYSE:GS) jumped 2.9% in the afternoon session after SpaceX made its market debut (the largest ...
Via StockStory · June 12, 2026
Brent Oil Drops Below $90 as the U.S. Closes in on a Peace Deal With Iran. What it Means for Oil Stocks.fool.com
Oil prices are declining amid hopes that the Strait of Hormuz will reopen soon.
Via The Motley Fool · June 12, 2026
CAVA (CAVA) Stock Trades Up, Here Is Why
What Happened? Shares of mediterranean fast-casual restaurant chain CAVA (NYSE:CAVA) jumped 2.6% in the afternoon session after the company raised its new re...
Via StockStory · June 12, 2026
Stay informed with the top movers within the dow jones index on Friday.chartmill.com
Via Chartmill · June 12, 2026
Investors: These 3 Marvelous Vanguard ETFs May Be the Smartest Buys Right Nowfool.com
One of the ETFs has averaged annual gains of 16.4% over the past 15 years.
Via The Motley Fool · June 12, 2026
Top dow jones movers in Friday's sessionchartmill.com
Via Chartmill · June 12, 2026
Applied Digital Is Building a $36 Billion AI Real Estate Empiremarketbeat.com
Applied Digital is successfully transitioning into a premier digital infrastructure landlord by securing massive hyperscaler commitments for its data centers.
Via MarketBeat · June 12, 2026
FNCL vs. KBWB: Broad Financial Exposure vs. a Concentrated Bank ETF -- Which Is the Better Buy?fool.com
Compare fees, risk profiles, and sector coverage between these two funds to see how their strategies could impact your investment approach.
Via The Motley Fool · June 12, 2026
argenx Eyes More VYVGART Growth as Pipeline Catalysts Nearmarketbeat.com
Executives at argenex (NASDAQ:ARGX) told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, while also pointing to a busy slate of pipeline readouts in the
Via MarketBeat · June 12, 2026
The SpaceX IPO Hinges on This $26.5 Trillion Growth Opportunityfool.com
SpaceX needs to capitalize on one key opportunity to justify its IPO valuation.
Via The Motley Fool · June 12, 2026
A Look Back at Data Analytics Stocks’ Q1 Earnings: Strategy (NASDAQ:MSTR) Vs The Rest Of The Pack
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Strategy (NASDAQ:MSTR) and it...
Via StockStory · June 11, 2026
Explore the top gainers and losers within the dow jones index in today's session.chartmill.com
Via Chartmill · June 11, 2026
Prediction: NextEra Energy's $67 Billion Dominion Acquisition Could Spur More Utility Deals. This Tie-Up Could be Next.fool.com
Any combination is possible. There's one particular one, however, that just makes good logistical and geographic sense.
Via The Motley Fool · June 11, 2026
Discover which dow jones stocks are making waves on Thursday.chartmill.com
Via Chartmill · June 11, 2026
Is Bloom Energy Impossible to Ignore Right Now? Here's What Smart Investors Should Know.fool.com
Bloom Energy's share price has lost nearly a quarter of its value from the recent peak.
Via The Motley Fool · June 11, 2026
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapymarketbeat.com
Capricor Therapeutics (NASDAQ:CAPR) executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy. Speaking at a Goldman Sac
Via MarketBeat · June 11, 2026
BrightSpring Health Services Sees Specialty Pharmacy, Tuck-In Deals Fueling Growthmarketbeat.com
BrightSpring Health Services (NASDAQ:BTSG) Chief Financial Officer Jennifer Phipps said the company’s recent growth has been driven by broad-based performance across its pharmacy and provider businesses, with specialty pharmacy remaining a key contributor. Speaking at a Goldman Sachs healthcare ser
Via MarketBeat · June 11, 2026
SpaceX Will Have Its IPO Tomorrow: 12 Things Retail Investors Should Knowfool.com
SpaceX will debut on the public markets, having raised at least $75 billion at a valuation of $1.78 trillion, making it the largest initial public offering ever.
Via The Motley Fool · June 11, 2026
Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Fundingmarketbeat.com
Apogee Therapeutics (NASDAQ:APGE) executives outlined plans to advance zumilokibart, the company’s IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the program into asthma and eosinophilic esophagitis, during a Goldman Sachs discussion hosted by lead biotec
Via MarketBeat · June 10, 2026
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shapemarketbeat.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference. Klee described avexitide as a
Via MarketBeat · June 10, 2026
Sweetgreen, CAVA, and Portillo's Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the CPI data showed food away from home rose only 0.3% in May, well within manageable...
Via StockStory · June 10, 2026
Kura Sushi and Yum China Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the CPI data showed food away from home rose only 0.3% in May, well within manageable...
Via StockStory · June 10, 2026
Mission Produce, Vita Coco, and Campbell's Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after markets rotated into defensive names following the release of the May CPI report. The...
Via StockStory · June 10, 2026
e.l.f. Beauty, B&G Foods, and Celsius Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after markets rotated into defensive names following the release of the May CPI report. The...
Via StockStory · June 10, 2026
Utz, Edgewell Personal Care, and WD-40 Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after markets rotated into defensive names following the release of the May CPI report. The...
Via StockStory · June 10, 2026